8-K 1 tm2012638d2_8k.htm 8-K




Washington, D.C. 20549









Date of Report (Date of earliest event reported): March 13, 2020 (March 11, 2020)


iBio, Inc.

(Exact name of registrant as specified in its charter)



(State or jurisdiction of incorporation or organization)



(Commission File Number)



(I.R.S. Employer Identification Number)


600 Madison Avenue, Suite 1601, New York, NY 10022-1737

(Address of principal executive offices (Zip Code)


Registrant's telephone number: (302) 355-0650



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


¨  Emerging growth company


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Ticker symbol(s)   Name of each exchange on which registered
Common Stock   IBIO   NYSE American






Item 8.01Other Events.




On March 11, 2020, iBio, Inc. (the “Company” or “iBio”) filed four provisional patent applications (the “Patent Applications”) that apply its Virus Like Particle [VLP] platform technology, or its lichenase carrier immunostimulatory (“LickM”) adjuvant technology, in conjunction with its FastPharmingManufacturing System for treating or preventing infections with the SARS-CoV-2 virus, which is the agent that causes coronavirus disease 2019 (COVID-19).


Master Joint Development Agreement with Beijing CC-Pharming Ltd.


On August 8, 2018, the Company and Beijing CC-Pharming Ltd. (“BCCP”) entered into a Master Joint Development Agreement (the “MJDA”) in which the Company and BCCP established a strategic commercial relationship for the joint development of products and manufacturing facilities for the Chinese biopharmaceutical market, utilizing iBio’s technology. The Company’s relationship with BCCP initially focused on the development of an oncology biosimilar or bio-better drug and license and transfer of the Company’s proprietary technology for drug development and manufacture to BCCP for use only in China.


When the coronavirus problems emerged in China, BCCP sought to extend the collaboration with the Company to process development and testing of coronavirus vaccine candidates. On February 6, 2020, the Company and BCCP executed a Statement of Work 2 (“SOW2”) memorializing their collaborative efforts to develop and test a new BCCP 2019-nCoV vaccine to be manufactured using iBio’s FastPharming System™.


The SOW2 is governed by the terms of the MJDA, which provides BCCP with a nonexclusive, non- assignable, non-sublicensable, limited license to use iBio technology in order to manufacture, process, prepare, and obtain regulatory approval for the development and production of biopharmaceuticals products based on iBio’s proprietary and patented plant-based protein production technology and know-how. The non-exclusive license granted under the MJDA extends only to China.


The contemplated collaborative effort with BCCP is still in early stages and has not yet progressed in any material respect.


The Company’s separate activities have resulted in the development of intellectual property in the field of vaccine candidate development for the SARS-CoV-2 virus. Those separate activities are reflected in the filing of the Patent Applications described above.


The foregoing descriptions of the terms of the SOW2 and MJDA do not purport to be complete and are subject to, and qualified in their entirety by reference to, such agreements, which are filed herewith as Exhibit 10.2, and Exhibit 10.1, respectively, and are incorporated herein by reference.


Item 9.01Exhibits


10.1Master Joint Development Agreement, dated as of August 8, 2018, between the Company and Beijing CC-Pharming Ltd.*


10.2Statement of Work 2, dated February 6, 2020, between the Company and Beijing CC-Pharming Ltd.*


* Portions of this exhibit, which are not material and would likely cause competitive harm to the Company if publicly disclosed, have been omitted. Omitted information is indicated by brackets in the exhibit.







         Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: March 13, 2020 By: /s/ Thomas F. Isett  
    Name: Thomas F. Isett  
    Title: Chief Executive Officer and  
      Executive Co-Chairman